The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes

Skelin, Marko; Lucijanić, Marko; Javor, Eugen

doi:10.1093/eurheartj/ehz242

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The hospital medicines policy design is a complex process, and requires an understanding of evidence-based medicine (EBM) and its translation into value-based medicine (VBM). The clinical pharmacist fulfilled these requirements by its competencies, [10][11][12][13][14][15][16][17][18] and was included in the DTC as an active member and redesigned the public procurement for medicines. The clinical pharmacist's approach in hospital medicines policy included encouraging rational, generic, therapeutically equivalent and biosimilar medicines prescribing, in line with regulations from the authorities, EBM and VBM data.…”

Section: Methodsmentioning

confidence: 99%

The economic impact of a clinical pharmacist’s involvement in the hospital medicines policy in a rural area

Javor

Allouch

Galic³

et al. 2021

Int J Clin Pract

Self Cite

View full text Add to dashboard Cite

Current trends in healthcare expenditures suggest an increase at alarmingly high rates. In Europe, the majority of the European Union (EU) Member States recorded a higher healthcare expenditure in 2016 compared with 2011. This trend was most pronounced in Estonia, where a 45.3% higher expenditure in 2016 was recorded, compared with 2011. 1 Considering the United States' of America (USA) total health care spending increased from an estimated $1.4 trillion [13.3% of gross domestic product (GDP)] in 1996 to an estimated $3.1 trillion (17.9% of GDP) in 2016. 2 The pharmaceutical expenditure accounts roughly for one-quarter of all healthcare expenditure, and is a significant driver of rising healthcare cost. 3 In Croatia average increase in expenditure for medicines from 2015 to 2019 was 9.8% annually. Even more worrisome is the increase of 15.5% in 2019 compared with 2018. 4 To optimise investment in medicines, hospitals design a hospital medicines policy and use tendering and negotiation processes.The European Parliament approved the new Directive on public procurement in 2014, to provide equal access with fair competition for public contracts within the EU market. 5 Currently, the lowest price procurement strategy, with generic prescribing included, is the most commonly used method by governments and hospitals in optimising investments in medicines. 6

show abstract

Section: Methodsmentioning

confidence: 99%

The economic impact of a clinical pharmacist’s involvement in the hospital medicines policy in a rural area

Javor

Allouch

Galic³

et al. 2021

Int J Clin Pract

Self Cite

View full text Add to dashboard Cite

show abstract

“…У дослідженні взяли участь 12 537 осіб із предіабетом чи ЦД, що були рандомізовані у групи за терапевтичними стратегіями: застосування інсуліну гларгіну та стандартного лікування. За результатами ро боти не виявлено різниці щодо виникнення будь-яких серцево-судинних подій, зокрема госпіталізацій із приводу ХСН [2,40]. У інших дослідженнях, присвячених стратегіям ліку вання ЦД, що включали інсулін, також не про демонстровано підвищення частоти розвит ку ХСН у хворих на інсулінотерапії [8].…”

Section: лікування хсн у пацієнтів із цд 2-го типуunclassified

Features of course and treatment of chronic heart failure in patients with diabetes mellitus type 2

Gorb

Strona

Ткаченко

et al. 2020

MTT

View full text Add to dashboard Cite

The epidemiology of chronic heart failure in patients with diabetes mellitus type 2, their general pathophysiological mechanisms, the influence of diabetes mellitus type 2 on the course and prognosis of chronic heart failure are considered. The high prevalence of chronic heart failure of all phenotypes among patients with diabetes mellitus type 2 and the increased risk of developing diabetes mellitus type 2 in patients with chronic heart failure confirm the close relationship and the high degree of comorbidity between these pathological conditions. It is shown that the development and progression of chronic heart failure in patients with diabetes mellitus type 2 is the formation of diabetic cardiomyopathy, which is characterized by disorders of energy metabolism of cardiomyocytes, mitochondrial dysfunction with subsequent apoptosis and myocardial fibrosis. Important links in the pathogenesis of chronic heart failure in diabetes mellitus type 2 are also the accession of diabetic cardiovascular autonomic neuropathy, activation of the renin-angiotensin-aldosterone system, endothelial dysfunction, exposure to atherogenic factors, arterial hypertension, obesity. The features of treatment of chronic heart failure in patients with diabetes mellitus type 2, the results of randomized clinical studies, the choice of target glycemic levels, the effectiveness of different groups of antihyperglycemic agents, drugs for the treatment of chronic heart failure, as well as their impact on the course and prognosis of chronic heart failure. Keywords: chronic heart failure, diabetes mellitus type 2, course, prognosis, treatment.

show abstract

Response to ‘The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes’

Bertero

Sequeira

Heymans

et al. 2019

European Heart Journal

View full text Add to dashboard Cite

The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes

Cited by 4 publications

References 5 publications

The economic impact of a clinical pharmacist’s involvement in the hospital medicines policy in a rural area

The economic impact of a clinical pharmacist’s involvement in the hospital medicines policy in a rural area

Features of course and treatment of chronic heart failure in patients with diabetes mellitus type 2

Response to ‘The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes’

Contact Info

Product

Resources

About